VIRX Stock - Viracta Therapeutics, Inc.
Unlock GoAI Insights for VIRX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | $120,000 | $2.07M |
| Gross Profit | $-492,000 | $-210,000 | $-178,000 | $88,000 | $2.07M |
| Gross Margin | N/A | N/A | N/A | 73.3% | 100.0% |
| Operating Income | $-50,693,000 | $-50,589,000 | $62.50M | $-18,815,000 | $-23,288,000 |
| Net Income | $-51,058,000 | $-49,774,000 | $-203,062,000 | $-19,199,000 | $-23,330,000 |
| Net Margin | N/A | N/A | N/A | -15999.2% | -1125.4% |
| EPS | $-1.32 | $-1.32 | $-6.37 | $-0.52 | $-0.97 |
Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. Its lead product candidature includes Nana-val, in combination with nanatinostat and valganciclovir that is in Phase II clinical trial for Epstein-Barr virus-positive lymphoma; and open-label Phase 2 basket trial for the treatment of various relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma, as well as an open-label Phase 1b/2 trial for the treatment of EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors. The company's development pipeline includes vecabrutinib, a clinical-stage non-covalent ITK/BTK inhibitor and VRx-510 (formerly SNS-510), a preclinical-stage PDK-1 inhibitor. It is evaluating development and collaboration opportunities for vecabrutinib in combination with chimeric antigen receptor T-cell therapies and VRx-510 in various oncology indications. The company was formerly known as Sunesis Pharmaceuticals, Inc. to Viracta Therapeutics, Inc. in February 25, 2021. Viracta Therapeutics, Inc. was incorporated in 1998 and is headquartered in Cardiff-by-the-Sea, California.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| August 16th 2024 | Leerink Partners | Downgrade | Market Perform | $3← $5 |
Earnings History & Surprises
VIRXEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2025 | Nov 11, 2025 | — | — | — | — |
Q3 2025 | Aug 18, 2025 | — | — | — | — |
Q2 2025 | May 29, 2025 | — | — | — | — |
Q1 2025 | Mar 28, 2025 | — | — | — | — |
Q4 2024 | Nov 13, 2024 | $-0.21 | $-0.27 | -28.6% | ✗ MISS |
Q3 2024 | Aug 14, 2024 | $-0.35 | $-0.25 | +28.6% | ✓ BEAT |
Q2 2024 | May 9, 2024 | $-0.35 | $-0.23 | +34.3% | ✓ BEAT |
Q1 2024 | Mar 7, 2024 | $-0.30 | $-0.35 | -16.7% | ✗ MISS |
Q4 2023 | Nov 9, 2023 | $-0.33 | $-0.33 | 0.0% | = MET |
Q3 2023 | Aug 14, 2023 | $-0.30 | $-0.32 | -6.7% | ✗ MISS |
Q2 2023 | May 8, 2023 | $-0.31 | $-0.32 | -3.2% | ✗ MISS |
Q1 2023 | Mar 13, 2023 | $-0.40 | $-0.27 | +32.5% | ✓ BEAT |
Q4 2022 | Nov 10, 2022 | $-0.31 | $-0.47 | -51.6% | ✗ MISS |
Q3 2022 | Aug 9, 2022 | $-0.30 | $-0.28 | +6.7% | ✓ BEAT |
Q2 2022 | May 10, 2022 | $-0.32 | $-0.28 | +12.5% | ✓ BEAT |
Q1 2022 | Mar 16, 2022 | $-0.47 | $-0.31 | +34.0% | ✓ BEAT |
Q4 2021 | Nov 10, 2021 | $-0.31 | $-0.40 | -29.0% | ✗ MISS |
Q3 2021 | Aug 12, 2021 | $-0.24 | $-0.25 | -4.2% | ✗ MISS |
Q2 2021 | May 12, 2021 | $0.10 | $0.38 | +266.8% | ✓ BEAT |
Q1 2021 | Feb 24, 2021 | $-0.96 | $-0.73 | +24.0% | ✓ BEAT |
Latest News
Frequently Asked Questions about VIRX
What is VIRX's current stock price?
What is the analyst price target for VIRX?
What sector is Viracta Therapeutics, Inc. in?
What is VIRX's market cap?
Does VIRX pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to VIRX for comparison